文献速递炎症性肠病消化内镜

内镜与组织学储袋炎评估工具的开发与外部验证:大西洋储袋炎指数

Development and External Validation of an Endoscopic and Histologic Pouchitis Assessment Tool: The Atlantic Pouchitis Index.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-07-16

研究基于98例慢性抗生素难治性储袋炎患者的随机安慰剂对照阿利卡福森试验视频和图像,开发并外部验证了一种新的内镜与组织学储袋炎评估工具——大西洋储袋炎指数(API)。API由克罗恩病简单内镜评分和Robarts组织病理学指数组成,评分范围0-69,表现出几乎完美的评分者内信度(ICC 0.88)和实质性的评分者间信度(ICC 0.72),以及高反应性(AUROC 0.95)。外部验证中,以维多珠单抗为变化标准时反应性良好(AUROC 0.63)。

要点

  • API由克罗恩病简单内镜评分和Robarts组织病理学指数组成,评分范围0-69。
  • API的评分者内信度ICC为0.88(95%CI 0.81-0.92),评分者间信度ICC为0.72(95%CI 0.60-0.79)。
  • API反应性AUROC为0.95(95%CI 0.89-0.98),优于现有内镜指数(ΔAUROC 0.09-0.24,P≤.005)。

核心结论

  • API的开发与验证推进了储袋炎疾病评估,整合内镜和组织病理学结果,形成客观、可靠且反应性好的工具,用于研究和临床环境中评估治疗效果。

研究设计与样本

  • 利用98例慢性抗生素难治性储袋炎患者(参与随机安慰剂对照阿利卡福森试验)的视频和图像,由内镜医师和病理学家使用11种现有指数(4种内镜、4种组织学、3种复合)及先前研发/加州大学洛杉矶分校适当性练习中的条目评估储袋炎疾病活动度。
  • 采用线性回归开发新指数,以储袋炎内镜和组织学疾病活动度的视觉模拟量表(VAS)为因变量,并使用EARNEST维多珠单抗试验数据进行外部验证。

主要发现

  • API表现出几乎完美的评分者内信度(ICC 0.88;95%CI 0.81-0.92)和实质性的评分者间信度(ICC 0.72;95%CI 0.60-0.79)。
  • 当变化标准为VAS下降半个标准差时,观察到高度反应性(AUROC 0.95;95%CI 0.89-0.98),优于现有内镜指数(ΔAUROC 0.09-0.24;P≤.005)。
  • 外部验证中,以维多珠单抗为变化标准时反应性良好(AUROC 0.63;95%CI 0.51-0.73)。

关键数值与推荐

  • API评分范围为0-69,由克罗恩病简单内镜评分和Robarts组织病理学指数组成。

临床怎么用

  • API可用于研究和临床环境中评估储袋炎治疗效果,整合内镜和组织病理学结果提供客观、可靠且反应性好的评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: No fully validated indices to measure pouchitis activity exist. We aimed to develop and externally validate a novel endoscopic and histologic index. METHODS: Endoscopists and pathologists used 11 (4 endoscopic, 4 histologic, 3 composite) existing indices and items from a prior Research and Development/University of California Los Angeles appropriateness exercise to assess pouchitis disease activity in videos and images from 98 patients with chronic antibiotic-refractory pouchitis who participated in a randomized placebo-controlled alicaforsen trial. Reliability was assessed with the intraclass correlation coefficient (ICC). Responsiveness was quantified by the area under the receiver operating characteristic curve (AUROC). A novel index was developed using linear regression with a visual analog scale (VAS) of pouchitis endoscopic and histologic disease activity as the dependent variable and was externally validated with the EARNEST vedolizumab trial data. RESULTS: The Atlantic Pouchitis Index (API) (range, 0-69) comprises the Simple Endoscopic Score for Crohn's Disease and Robarts Histopathology Index. The API exhibited almost perfect intra-rater (ICC, 0.88; 95% confidence interval [CI], 0.81-0.92) and substantial inter-rater reliability (ICC, 0.72; 95% CI, 0.60-0.79). A high degree of responsiveness (AUROC, 0.95; 95% CI, 0.89-0.98), greater than existing endoscopic indices (ΔAUROC, 0.09-0.24; P ≤ .005), was observed when the change criterion was a decrease in the VAS of one-half of the standard deviation. Good responsiveness was observed in external validation when vedolizumab was the change criterion (AUROC, 0.63; 95% CI, 0.51-0.73). CONCLUSIONS: Development and validation of the API advances pouchitis disease assessment. Integration of endoscopy and histopathology results in an objective, reliable, and responsive instrument to evaluate therapy effectiveness in research and clinical settings.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sedano R, Ma C, Hogan M, et al. Development and External Validation of an Endoscopic and Histologic Pouchitis Assessment Tool: The Atlantic Pouchitis Index. Clin Gastroenterol Hepatol. 2025. PMID: 40675404. doi:10.1016/j.cgh.2025.06.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。